Quarterly Inactive Ingredient Database (IID) Change Log

Why It Matters

Accurate IID data is critical for pharmaceutical formulation, regulatory compliance, and patient safety, making quarterly revisions a key operational checkpoint for drug developers.

Key Takeaways

• FDA releases quarterly IID updates with corrected, deleted, and MDE‑replaced records
• Log excludes new excipient entries; they appear on main IID page
• MDE replacements reflect higher maximum daily exposure values from FDA master database
• Corrections often adjust ingredient name, unit, or potency, improving data accuracy
• Deletions usually result from route or dosage‑form changes that generate new records

Pulse Analysis

The Inactive Ingredient Database (IID) serves as the FDA’s authoritative source for excipient information, cataloguing everything from chemical names to potency limits. By publishing the IID quarterly, the agency provides a living document that reflects the evolving landscape of drug formulation, ensuring that manufacturers have a single, vetted reference for safety thresholds and labeling requirements. This systematic approach reduces reliance on disparate data sources and streamlines the regulatory review process for new drug applications.

Each quarterly Change Log captures three distinct categories of modifications: corrected records that amend ingredient names, units of measure, or potency values; deleted records that are removed after a route‑of‑administration or dosage‑form correction creates a new entry; and MDE replacements where a higher Maximum Daily Exposure is identified in the FDA’s master database. While the log does not list brand‑new excipients—those appear on the main IID page—it offers a transparent audit trail of how the database’s integrity improves over time. For formulators, tracking these adjustments is essential to avoid compliance gaps, especially when potency decreases could affect dosage calculations.

Looking ahead, the phased integration of MDE values signals a shift toward more nuanced exposure assessments, potentially supplanting traditional maximum potency figures. As the FDA continues to refine the IID, companies that proactively monitor the Change Log will be better positioned to anticipate formulation revisions, mitigate risk, and accelerate product launches. In a market where regulatory agility can dictate competitive advantage, staying current with IID updates is no longer optional—it’s a strategic imperative.